Cognition Therapeutics Inc CGTX
Cognition Therapeutics Inc (Nasdaq: CGTX) is a CNS/neurology/psychiatry drug developer. Its lead program, zervimesine (CT1812), is in Phase 2 for Alzheimer's disease (AD) mild cognitive impairment (MCI) and early stage. Its next catalyst on record is zervimesine (CT1812) – Alzheimer's disease (MCI/early): START topline results after all participants complete 18 months of treatment (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: zervimesine (CT1812) – Alzheimer's disease (MCI/early) — START topline results after all participants complete 18 months of treatment (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| zervimesine (CT1812) | Alzheimer's disease (MCI and early stage) | small molecule | Phase 2 |
| zervimesine (CT1812) | Alzheimer's disease (mild-to-moderate) | small molecule | Phase 2 |
| zervimesine (CT1812) | dementia with Lewy bodies (DLB) | small molecule | Phase 2 |
| zervimesine (CT1812) EAP | dementia with Lewy bodies (DLB) | small molecule | Phase 2 |
| zervimesine (CT1812) | geographic atrophy secondary to dry AMD | small molecule | Phase 2 |
Recent results and decisions
- Oct 22, 2026n/a Cognition Therapeutics announces FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine in dementia with Lewy bodies.
With FDA's alignment on trial design, we are completing a protocol to support the planned registrational study in DLB, a disease with no approved treatments.
Filing - Jun 24, 2026positive Recent analysis of Phase 2 SHIMMER: zervimesine slowed progression of hallucinations and delusions by 89% vs placebo.
In a recent analysis of results from the Phase 2 study, zervimesine slowed progression of hallucinations and delusions by 89%.
Filing - Mar 26, 2026completed enrollment Enrollment completed (December 2025) in the 545-patient Phase 2 START trial; topline expected 2027.
Our 545-patient ‘START’ trial in early Alzheimer’s disease has completed enrollment.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.